4428-95-9 Usage
Originator
Foscarnet Sodium,AstraZeneca,USA
Manufacturing Process
423 g (4.77 mol) of sodium hydroxide is added to 400 ml of water. The
solution is heated to about 50°C and 167 g (0.795 mol) of triethyl
phosphonoformate is added. The reaction mixture is then heated to about
90°C and ethanol formed is distilled off. After about 1 hour at 90-95°C the
reaction mixture is cooled to about 20°C and the product is filtered off. The
yield of trisodium phosphonoformate hexahydrate wet is 248 g.
The wet substance is recrystallized in 570 ml of water by heating to 423 g
(4.77 mol) of sodium hydroxide liquid conc. is added to 400 ml of water. The
solution is heated to about 50°C and 167 g (0.795 mol) of triethyl
phosphonoformate is added at this temperature. The reaction mixture is then
heated to about 90°C and ethanol formed is distilled off. After about 1 hour at
90-95°C the reaction mixture is cooled to about 20°C and the product is
filtered off. The yield of trisodium phosphonoformate hexahydrate wet is 248
g.
The wet substance is recrystallized in 570 ml of water by heating to 90°C in
order to obtain a clear solution and then cooling to about 20°C. After filtration
and washing with 50 ml of water at 18-22°C 187 g (74% of theoretical yield)
of trisodium phosphonoformate hexahydrate is obtained. This substance
contains about 2% free water, which can be eliminated by drying.
Therapeutic Function
Antiviral
Enzyme inhibitor
This pyrophosphate analogue (FWtrisodium salt = 191.95 g/mol; CAS 4428-95-
9), also called foscarnet, exhibits antiherpetic activity. It is a stro+ng inhibitor
of viral reverse transcriptases and viral replication as well as Na/phosphate
cotransporters. Target (s) : adenylyl cyclase; avian myeloblastosis virus
reverse transcriptase; cytomegalovirus DNA polymerase (4-6); DNA-
directed DNA polymerase; DNA polymerase b; DNA
polymerases, viral; duck hepatitis B virus reverse transcriptase
; Epstein-Barr virus DNA polymerase; equine infectious
anemia virus reverse transcriptase; exoribonuclease H; feline
immunodeficiency virus reverse transcriptase; geranyl-diphosphate
cyclase, or bornyl-diphosphate synthase; guanylyl cyclase; HIV-1
reverse transcriptase; human T-lymphotropic
virus type III reverse transcriptase; herpes virus reverse transcriptase
; human hepatitis B virus reverse transcripta+se;
Moloney murine leukemia virus reverse transcriptase; Na-dependent
phosphate transport (32-38); phosphoenolpyruvate carboxylase;
phosphoenolpyruvate mutase; phosphonoacetate hydrolase;
phosphonopyruvate hydrolase; ribonuclease H; RNA-directed
DNA polymerase; simian immunodeficiency virus
reverse transcriptase; and woodchuck hepatitis virus reverse
transcriptase.
Check Digit Verification of cas no
The CAS Registry Mumber 4428-95-9 includes 7 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 4 digits, 4,4,2 and 8 respectively; the second part has 2 digits, 9 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 4428-95:
(6*4)+(5*4)+(4*2)+(3*8)+(2*9)+(1*5)=99
99 % 10 = 9
So 4428-95-9 is a valid CAS Registry Number.
InChI:InChI=1/CH3O5P/c2-1(3)7(4,5)6/h(H,2,3)(H2,4,5,6)
4428-95-9Relevant academic research and scientific papers
Pharmaceutical formulation
-
, (2008/06/13)
PCT No. PCT/SE96/00123 Sec. 371 Date Mar. 8, 1996 Sec. 102(e) Date Mar. 8, 1996 PCT Filed Feb. 2, 1996 PCT Pub. No. WO96/24359 PCT Pub. Date Aug. 15, 1996The invention relates to a pharmaceutical composition for topical administration comprising a combination of foscarnet and an antiinflammatory glucocorticoid, in admixture with a carrier based on galactolipids and a polar solvent. The pharmaceutical composition can be used in a prophylactic and/or curative treatment of herpesvirus infections in mammals including man. The invention also relates to the use of said pharmaceutical composition in the manufacture of a medicament for said prophylactic or curative treatment.
PHOSPHONOFORMIC ACID ESTERS
-
, (2008/06/13)
A compound of the formula, wherein R1, R2 and R3 are the same or different, and each is selected from the group consisting of hydrogen and phenyl groups of the formula, wherein R4 and R5 are the same or different and each is selected from the group consis
